Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 247 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cord Blood Transplant Clear all
Completed Phase 2 Interventional Results available

Sitagliptin Umbilical Cord Blood Transplant Study

NCT00862719
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Acute Lymphoblastic Leukemia, Myelodysplasia, Leukemia, Myelogenous, Chronic, Lymphoma, Non-Hodgkin
Interventions
Sitagliptin
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 59 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 4, 2026, 5:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM

NCT01816230
View directory record Official record
Conditions
Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
NiCord®
Drug
Lead sponsor
Gamida Cell ltd
Industry
Eligibility
12 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
8
States / cities
Los Angeles, California • Maywood, Illinois • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 4, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

NCT00919503
View directory record Official record
Conditions
Non-Neoplastic Hematologic and Lymphocytic Disorder
Interventions
Allogeneic Bone Marrow Transplantation, Anti-Thymocyte Globulin, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation, Treosulfan, Umbilical Cord Blood Transplantation
Procedure · Biological · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 49 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
6
States / cities
Aurora, Colorado • Portland, Oregon • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 4, 2026, 5:37 PM EDT
Completed Phase 1Phase 2 Interventional

Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers

NCT00089596
View directory record Official record
Conditions
Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Chronic Myelogenous Leukemia
Interventions
Expansion of umbilical cord stem cells
Procedure
Lead sponsor
ViaCell
Industry
Eligibility
12 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
4
States / cities
Maywood, Illinois • Indianapolis, Indiana • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2007 · Synced Oct 4, 2026, 5:37 PM EDT
Terminated Phase 1 Interventional Results available

A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders

NCT02354443
View directory record Official record
Conditions
Metabolic Disorders
Interventions
ProHema-CB Transplant
Biological
Lead sponsor
Fate Therapeutics
Industry
Eligibility
1 Year to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 4, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission

NCT00382109
View directory record Official record
Conditions
B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Graft Versus Host Disease, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
Interventions
thiotepa, cyclophosphamide, tacrolimus, methotrexate, sirolimus, total body irradiation
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
44
States / cities
Phoenix, Arizona • Duarte, California • Oakland, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 4, 2026, 5:37 PM EDT
Terminated Phase 1 Interventional Results available

A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies

NCT02354417
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Biological: ProHema-CB
Biological
Lead sponsor
Fate Therapeutics
Industry
Eligibility
1 Year to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Duarte, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 4, 2026, 5:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs

NCT01033552
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
Cyclophosphamide, Fludarabine, Anti-thymocyte globulin, Myeloablative Busulfan, Mesenchymal stem cell transplantation, Total body irradiation, Bone marrow or umbilical cord blood (UCG) stem cell transplantation
Drug · Procedure · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 25 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 4, 2026, 5:37 PM EDT
Completed Phase 1 Interventional

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

NCT01471067
View directory record Official record
Conditions
Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection, Transplantation, Bone Marrow
Interventions
Melphalan, Fludarabine, Mycophenolate mofetil, Tacrolimus, Cord Blood Infusion, Rituximab, ATG, Busulfan, Clofarabine, Total Body Irradiation (TBI)
Drug · Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 4, 2026, 5:37 PM EDT
Recruiting Phase 2 Interventional

Cord Blood Transplant in Adults With Blood Cancers

NCT05884333
View directory record Official record
Conditions
Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndromes (MDS), Myeloproliferative Disorder, Non-Hodgkin's Lymphoma
Interventions
Conditioning Chemotherapy, Cord blood graft
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 4, 2026, 5:37 PM EDT
Completed No phase listed Observational

IMPAACT P1107: Effects of Cord Blood Transplantation With CCR5Δ32 Donor Cells on HIV Persistence

NCT02140944
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
12 Months and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 4, 2026, 5:37 PM EDT
Completed Phase 1 Interventional Results available

Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders

NCT00744692
View directory record Official record
Conditions
Non Malignant Disorders, Immunodeficiencies, Congenital Marrow Failures, Hemoglobinopathies, Inborn Errors of Metabolism, Sickle Cell, Thalassemia, Lysosomal Storage Disease
Interventions
Unrelated Umbilical Cord Blood Transplant, Reduced Intensity Conditioning
Biological · Drug
Lead sponsor
Duke University
Other
Eligibility
Up to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Oct 4, 2026, 5:37 PM EDT
Withdrawn Phase 1 Interventional

UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies

NCT00578045
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Transfusion
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Oct 4, 2026, 5:37 PM EDT
Completed Phase 1 Interventional

Phase I Study of Sequential Cord Blood Transplants

NCT00299767
View directory record Official record
Conditions
Lymphoma, Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
Interventions
sequential cord blood transplantation
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Up to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Oct 4, 2026, 5:37 PM EDT
Completed Phase 2 Interventional

US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia

NCT04103879
View directory record Official record
Conditions
High Risk Hematological Malignancy, Cord Blood Transplant
Interventions
ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Biological
Lead sponsor
ExCellThera inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 4, 2026, 5:37 PM EDT
Terminated Phase 2 Interventional Results available

Cord Blood Transplantation for Patients With Cancer

NCT01359254
View directory record Official record
Conditions
Hematological Disease
Interventions
Melphalan, Fludarabine, Antithymocyte Globulin (ATG), Busulfan, Total Body Irradiation (TBI)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 4, 2026, 5:37 PM EDT
Terminated Phase 1 Interventional

Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant

NCT00737113
View directory record Official record
Conditions
Allogeneic Stem Cell Transplantation
Interventions
Genotropin (Recombinant Human Growth Hormone)
Drug
Lead sponsor
Mitchell Horwitz, MD
Other
Eligibility
12 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2014 · Synced Oct 4, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant

NCT00305682
View directory record Official record
Conditions
Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, cyclophosphamide, Fludarabine, mycophenolate mofetil, umbilical cord blood transplantation, total body irradiation, Sirolimus
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 4, 2026, 5:37 PM EDT
Completed Phase 2Phase 3 Interventional Results available

TBI Dose De-escalation for Fanconi Anemia

NCT00352976
View directory record Official record
Conditions
Fanconi Anemia
Interventions
Cyclophosphamide, Fludarabine, Total Body Irradiation, Bone Marrow Transplantation, Mycophenolate Mofetil, Sirolimus
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 4, 2026, 5:37 PM EDT
Recruiting Phase 2 Interventional

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

NCT01962415
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
Interventions
Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 4, 2026, 5:37 PM EDT
Terminated Phase 2 Interventional Results available

Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies

NCT02991898
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Natural Killer Cell Malignancies, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Large-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Hodgkin Lymphoma, Multiple Myeloma, Acute Myelogenous Leukemia, Biphenotypic Leukemia, Undifferentiated Leukemia
Interventions
Infusion of Treg
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 4, 2026, 5:37 PM EDT
Terminated Phase 2 Interventional Results available

Preservation of Ovarian Function After Hematopoietic Cell Transplant

NCT01343368
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease, Acute Myeloid Leukemia, Myeloproliferative Disorders
Interventions
Leuprolide, hematopoietic cell transplant, reduced intensity allogeneic HCT
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
50 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 4, 2026, 5:37 PM EDT
Terminated Phase 2 Interventional

Reduced Intensity AlloSCT in(CML) With Persistent Disease

NCT00531310
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Reduced Intensity Conditioning, Busulfan and Fludarabine
Drug
Lead sponsor
Columbia University
Other
Eligibility
Up to 30 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 4, 2026, 5:37 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers

NCT00539656
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Leukemia, Bilineage, Acute, Leukemia, Myeloid, Chronic
Interventions
Ex vivo expansion of cord blood
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Oct 4, 2026, 5:37 PM EDT